Plus Therapeutics: Plus Therapeutics: ReSPECT-LM Data Shows Potential Utility Of REYOBIQ

WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) reported the online availability of new data on its lead compound REYOBIQ. The additional data from the Phase 1 ReSPECT-LM dose escalation trial dem...